Aryl receptor modulators and methods of making and using the same

US12577256B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12577256-B2
Application numberUS-202418656965-A
CountryUS
Kind codeB2
Filing dateMay 7, 2024
Priority dateJun 27, 2014
Publication dateMar 17, 2026
Grant dateMar 17, 2026

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention is generally directed towards compounds capable of binding the aryl hydrocarbon receptor and modulating its activity, methods of treating inflammatory conditions such as Crohn's disease using such compounds, and pharmaceutical compositions comprising such compounds. Also provided are methods of increasing levels of IL-22 in a subject and/or decreasing levels of IFN-7 in a subject.

First claim

Opening claim text (preview).

What is claimed is: 1 . A compound represented by: or a pharmaceutically acceptable salt thereof. 2 . A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. 3 . A method of treating or reducing fibrostenosis or intestinal fibrosis in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof. 4 . A compound represented by: or a pharmaceutically acceptable salt thereof. 5 . A pharmaceutical composition comprising a compound according to claim 4 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. 6 . A method of treating or reducing fibrostenosis or intestinal fibrosis in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 4 , or a pharmaceutically acceptable salt thereof.

Assignees

Inventors

Classifications

  • Nitrogen atoms · CPC title

  • Nitrogen atoms · CPC title

  • with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 · CPC title

  • Nitrogen atoms not forming part of a nitro radical · CPC title

  • Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12577256B2 cover?
The present invention is generally directed towards compounds capable of binding the aryl hydrocarbon receptor and modulating its activity, methods of treating inflammatory conditions such as Crohn's disease using such compounds, and pharmaceutical compositions comprising such compounds. Also provided are methods of increasing levels of IL-22 in a subject and/or decreasing levels of IFN-7 in a …
Who is the assignee on this patent?
Nogra Pharma Ltd
What technology area does this patent fall under?
Primary CPC classification C07D209/94. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 17 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 11 related publications on this page (citations in our corpus or others sharing the same primary CPC).